CV protection by SGLT2 inhibition: Potential mechanisms for benefit
Disclosures
Prof. Hiddo Lambers Heerspink - Department of Clinical Pharmacology, University Medical Center Groningen, The Netherlands
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: